GSK's boasts on triple therapy questioned in editorial

19 April 2018

GlaxoSmithKline (LSE: GSK) has highlighted the publication of data on its triple therapy Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) in the New England Journal of Medicine (NEJM), but the UK pharma major might not want to draw so much attention to an accompanying editorial.

NEJM has published findings on Trelegy, a therapy developed by GSK and its partner Innoviva (Nasdaq: INVA), from the IMPACT study, one of the largest ever conducted in patients with chronic obstructive pulmonary disease (COPD) with a history of exacerbation.

Findings from the study suggest that the triple combination is superior to the Relvar/Reo Ellipta (fluticasone furoate/vilanterol) and Anoro Ellipta (umeclidinium/vilanterol) dual therapies that were earlier developed by GSK, across multiple endpoints including exacerbations, lung function and quality of life.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK